Start a New Search
SHOWING 74 RESULTS
Dr. Michael R. Crum testifies before the U.S. Senate Committee on the Judiciary Hearing on “The Impact of Abusive Patent Litigation Practices on the American Economy.”
Intellectual Property | Patents | Testimony145 universities warn congress pending patent legislation would harm U.S. Innovation System.
Intellectual Property | Patents | LettersSix higher education associations support tailored legislation to combat patent trolls, say provisions of innovation act would debilitate U.S. patent system.
Intellectual Property | Patents | StatementsA broad coalition, whose members represent the majority of the nation’s patent holders and inventors, strongly oppose legislation that would weaken the overall patent system and thereby diminish innovation and job creation in the United States.
Intellectual Property | Patents | LettersUniversities express concern that several proposals intended to target troll-like behavior do not in their current form meet the cost/benefit test of curbing abusive patent litigation practices without diminishing the value of
patents.
Intellectual Property | Patents | LettersRecent developments in the federal courts, the U.S. Patent and Trademark Office (USPTO), and the Federal Trade Commission (FTC) have dramatically reduced abusive patent litigation while ensuring that job creating innovators can continue to protect their ideas, eliminating the need for broad new…
Intellectual Property | Patents | Fact SheetsA broad coalition ranging from universities and non-profit foundations, start-ups and small businesses, manufacturing, technology, and life sciences companies, strongly oppose legislation that would weaken the overall patent system and thereby diminish innovation and job creation in the United…
Intellectual Property | Patents | LettersOn behalf of the Association of American Universities (AAU), I would like to thank you for the opportunity to provide comments to the Committee on Commerce, Science, and Transportation on the reauthorization of the America COMPETES Act.
Innovation and Competitiveness | National Science Foundation | Department of Energy | Reducing Regulatory Burden | LettersRe: Retrospective Review: Identifying and Reducing Regulatory Burdens; 81 FR 4213
Research Administration & Regulation | Reducing Regulatory Burden | LettersIn the US, ketamine is currently a Schedule III drug under the Controlled Substances Act, and strict regulations and safeguards are already in place to prevent its illegal use.
Research Administration & Regulation | Reducing Regulatory Burden | Higher Education Regulation | Letters